| Autor: |
McGovern, AP, Dennis, JM, Shields, BM, Hattersley, AT, Pearson, ER, Jones, AG, Farmer, AJ, Mastermind Consortium |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Zdroj: |
BMC Medicine. 17 |
| ISSN: |
1741-7015 |
| Popis: |
BACKGROUND:It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addressed this issue. METHODS:In a retrospective cohort analysis using the UK Clinical Practice Research Datalink (CPRD), we assessed the outcome of 55,530 patients with type 2 diabetes starting their second or third non-insulin glucose-lowering medication, with a baseline HbA1c > 58 mmol/mol (7.5%). For those with no HbA1c improvement or a limited response at 6 months (HbA1c fall |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink